Hypoglycaemia exacts extra costs in Canada

July 2010
PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p7
The article discusses research on the association of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients in Canada, referencing a study by M. Bron and colleagues presented at the 70th Annual Scientific Sessions of the American Diabetes Association.


Related Articles

  • The Direct Medical Cost of Type 2 Diabetes. Brandle, Michael; Zhou, Honghong; Smith, Barbara R.K.; Marriott, Deanna; Burke, Ray; Tabaei, Bahman P.; Brown, Morton B.; Herman, William H. // Diabetes Care;Aug2003, Vol. 26 Issue 8, p2300 

    OBJECTIVE — To describe the direct medical costs associated with type 2 diabetes, as well as its treatments, complications, and comorbidities. RESEARCH DESIGN AND METHODS — We studied a random sample of 1,364 subjects with type 2 diabetes who were members of a Michigan health...

  • Type 2 Diabetes: Incremental Medical Care Costs During the First 8 Years After Diagnosis. Brown, Jonathan B.; Nichols, Gregory A.; Glauber, Harry S.; Bakst, Alan W. // Diabetes Care;Jul99, Vol. 22 Issue 7, p1116 

    Presents information on a study that described and analyzed the time course of medical care costs caused by type 2 diabetes, from the time of diagnosis through the first postdiagnostic years. Research design and methods; Results; Conclusions.

  • Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Haak, Thomas // Clinical Medicine Insights: Endocrinology & Diabetes;2015, Issue 8, p1 

    Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor...

  • Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort. Rhee, Sang Youl; Hong, Soo Min; Chon, Suk; Ahn, Kyu Jeung; Kim, Sung Hoon; Baik, Sei Hyun; Park, Yong Soo; Nam, Moon Suk; Lee, Kwan Woo; Woo, Jeong-Taek; Kim, Young Seol // PLoS ONE;2/18/2016, Vol. 11 Issue 2, p1 

    Background and Aims: Hypoglycemia is one of the most important adverse events in individuals with type 2 diabetes mellitus (T2DM). However, hypoglycemia-related events are usually overlooked and have been documented less in clinical practice. Materials and Methods: We evaluated the incidence,...

  • Intensive blood glucose control for type 2 diabetes: meta-analysis.  // Africa Health;Mar2012, Vol. 34 Issue 3, p59 

    The article reports on a meta-analysis of intensive blood glucose control for type 2 diabetes, which found that intensive control could not minimize all-cause mortality, however, can increase the risk of severe hypoglycaemia by about 30%.

  • Exenatide more effective than insulinglargine in patients with type 2 diabetes.  // Australian Journal of Pharmacy;Feb2011, Vol. 92 Issue 1089, p71 

    The article presents a case study on the efficacy of exenatide on patients with type 2 diabetes. In the study, exenatide was compared with insulin gargine in adults with type 2 diabetes who had subtimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for...

  • Antibacterials/insulin detemir/omeprazole interaction.  // Reactions Weekly;8/1/2013, Issue 1463, p9 

    The article presents a case study of an 82-year-old man with hypoglycaemia, which developed during treatment with amoxicillin, clarithromycin, omeprazole and insulin detemir for type 2 diabetes.

  • PEDIATRIC MANAGEMENT PROBLEMS. Belkengren, Richard; Sapala, Shirley // Pediatric Nursing;Mar/Apr2000, Vol. 26 Issue 2, p182 

    Presents the case of a 14-year-old female with Type I diabetes. Social and family history; Factors that contributed to the occurrence of hypoglycemia; Treatment for the disease.

  • New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence. Miller, Brien Rex; Hanh Nguyen; Jia-Haur Hu, Charles; Chihyi Lin; Quang T. Nguyen // American Health & Drug Benefits;Nov2014, Vol. 7 Issue 8, p452 

    BACKGROUND: Diabetes is a deadly and costly disease. The number of adults in the United States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current pace, 1 in 3 US adults will have diabetes in their lifetime. Currently, 14 classes of drugs are available to treat...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics